ResearchMoz

Pharmaceuticals Monthly Deals Analysis: October 2013 - Partnerships, Licensing, Investments and M&A Trends

GlobalData
Published Date » 2013-11-30
No. Of Pages » 107
   
 GlobalData's Pharmaceuticals Monthly Deals Analysis: October 2013 Partnerships, Licensing, Investments and M&A Trends report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in October 2013. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals...
Table of Contents

1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 5
1.2 List of Figures 8

2 Pharmaceuticals & Healthcare, Global, Deal Summary 12
2.1 Pharmaceuticals & Healthcare, Global, Deal Analysis, October 2013 12
2.2 Pharmaceuticals & Healthcare, Global, Major Deals, October 2013 14
2.2.1 McKesson to Acquire Celesio for US$8.3 Billion 14
2.2.2 Bristol-Myers Squibb Completes Public Offering of Notes for US$1.5 Billion 16
2.2.3 Ventas Acquires Portfolio of Independent Living Communities from Holiday Retirement for US$790 Million 16
2.2.4 BioMarin Pharma Completes Public Offering of Notes for US$750 Million 16
2.2.5 Astellas Pharma Enters Into R&D Agreement with Mitokyne for Drug Discovery 17
2.3 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, October 2013 18
2.4 Pharmaceuticals & Healthcare, Global, by Type, Deal Values, October 2013 19

3 Pharmaceuticals and Healthcare, Global, Deals, Summary, by Type 20
3.1 Pharmaceuticals & Healthcare, Global, M&A, October 2013 20
3.1.1 Top M&A Deals in October 2013 21
3.1.2 Pharmaceuticals & Healthcare, Global, M&A Deals by Therapy Area, May 2013 - October 2013 22
3.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, October 2013 23
3.2.1 Top Equity Offering Deals in October 2013 24
3.2.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, May 2013 - October 2013 25
3.3 Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital Deals, October 2013 27
3.3.1 Top PE/VC Deals in October 2013 28
3.3.2 Pharmaceuticals & Healthcare, Global, PE/VC by Therapy Area, October 2013 29
3.3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, October 2013 31
3.3.4 Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, May 2013-October 2013 33
3.3.5 Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, May 2013-October 2013 34

4 Pharmaceuticals & Healthcare, Global, Partnership Deals, October 2013 35
4.1 Pharmaceuticals & Healthcare, Global, Partnership Deals, October 2013 35
4.2 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, May 2013 - October 2013 37
4.3 Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payments and Deal Values (US$ m), October 2013 39
4.3.1 Pharmaceuticals & Healthcare, Global, Top Partnership Deals by Payment Mode, October 2013 41
4.4 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), May 2013 - October 2013 42
4.5 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Number Of Deals, May 2013 - October 2013 44
4.6 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Deal Values (US$ m), May 2013 - October 2013 45
4.7 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), May 2013 - October 2013 47

5 Pharmaceuticals & Healthcare, Global, Licensing Agreements, October 2013 49
5.1 Pharmaceuticals & Healthcare, Global, Licensing Agreements, October 2013 49
5.2 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), October 2013 51
5.2.1 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Deal Value, October 2013 53
5.2.2 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, October 2013 53
5.2.3 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Total Milestone Payment, October 2013 54
5.3 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Total Deal Values (US$ m), May 2013 - October 2013 55
5.4 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront Payments and Milestone Payments (US$ m), May 2013 - October 2013 57
5.5 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Total Deal Values (US$ m), May 2013 - October 2013 59
5.6 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Upfront Payments and Milestone Payments (US$ m), May 2013 - October 2013 61

6 Pharmaceuticals & Healthcare, Global, Deal Summary by Therapy Area 63
6.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, October 2013 63
6.1.1 Oncology - Deals of the Month 65
6.2 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, October 2013 67
6.2.1 Central Nervous System - Deals of the Month 69
6.3 Pharmaceuticals & Healthcare, Global, Immunology Deals, October 2013 70
6.3.1 Immunology - Dealsof the Month 72
6.4 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, October 2013 73
6.4.1 Infectious Diseases - Deals of the Month 75
6.5 Pharmaceuticals & Healthcare, Global, Metabolic Disorder Deals, October 2013 76
6.5.1 Metabolic Disorders - Deal of the Month 78
6.6 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, October 2013 81
6.6.1 Cardiovascular - Deal of the Month 82
6.7 Pharmaceuticals & Healthcare, Global, Hematological Disorders, Deals, October 2013 84
6.7.1 Hematological Disorders - Deal of the Month 85

7 Deal Summary by Geography 87
7.1 Pharmaceuticals & Healthcare, North America Deals, October 2013 87
7.1.1 North America - Deals of the Month 89
7.2 Pharmaceuticals & Healthcare, Europe, Deals, October 2013 91
7.2.1 Europe - Deals of the Month 92
7.3 Pharmaceuticals & Healthcare, Asia-Pacific, Regional Deals, October 2013 94
7.3.1 Asia-Pacific - Deals of the Month 96
7.4 Pharmaceuticals & Healthcare, Rest of the World, Deals, October 2013 97
7.4.1 Rest of the World - Deals of the Month 99

8 Pharmaceuticals & Healthcare, Global, Top Financial Advisors 100
8.1 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, May 2013 - October 2013 100
8.2 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, May 2013 - October 2013 102

9 Further Information 104
9.1 Methodology 104
9.2 About GlobalData 105
9.3 Disclosure information 106
9.4 Disclaimer 106

List of Tables


Table 1: Pharmaceuticals & Healthcare, Global, Deals Summary, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 13
Table 2: Pharmaceuticals & Healthcare, Global, Major Deals, October 2013 14
Table 3: Pharmaceuticals & Healthcare, Global, Number Of Deals and Deal Values (%), October 2013 19
Table 4: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 21
Table 5: Pharmaceuticals & Healthcare, Global, Top M&A Deals, October 2013 21
Table 6: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), by Therapy Area, May 2013 - October 2013 22
Table 7: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 24
Table 8: Pharmaceuticals & Healthcare, Global, Top Equity Offering Deals, October 2013 24
Table 9: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 26
Table 10: Pharmaceuticals & Healthcare, Global, PE/VC, Deals Summary, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 28
Table 11: Pharmaceuticals & Healthcare, Global, Top PE/VC Deals, October 2013 28
Table 12: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Deals Summary, May 2013 - October 2013 30
Table 13: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals and Deal Values (%), October 2013 32
Table 14: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 33
Table 15: Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, May 2013 - October 2013 34
Table 16: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 36
Table 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 38
Table 18: Pharmaceuticals & Healthcare, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), May 2013 - October 2013 40
Table 19: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront and Milestone Payments and Deal Values (US$ m), October 2013 41
Table 20: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), May 2013 - October 2013 43
Table 21: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, May 2013 - October 2013 46
Table 22: Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payment and Deal values (US$ m), May 2013 - October 2013 48
Table 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deals Summary, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 50
Table 24: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Deals Summary, Upfront and Milestone Payments and Deal Values (US$ m), May 2013 - October 2013 52
Table 25: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Value, October 2013 53
Table 26: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Upfront Payments, October 2013 53
Table 27: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Milestone Payment, October 2013 54
Table 28: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 56
Table 29: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments (US$ m), October 2013 58
Table 30: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, May 2013 - October 2013 60
Table 31: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), October 2013 62
Table 32: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 64
Table 33: Pharmaceuticals & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 68
Table 34: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 71
Table 35: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Deals Summary, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 74
Table 36: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 77
Table 37: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 82
Table 38: Pharmaceuticals & Healthcare, Global, Hematological Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 85
Table 39: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 88
Table 40: Pharmaceuticals & Healthcare, Europe, Deals Summary, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 92
Table 41: Pharmaceuticals & Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 95
Table 42: Pharmaceuticals & Healthcare, Rest of the World, Deals Summary, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 98
Table 43: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 101
Table 44: Pharmaceuticals & Healthcare, Global Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 103

List of Figures


Figure 1: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 12
Figure 2: Pharmaceuticals & Healthcare, Global, Number Of Deals (%), October 2013 18
Figure 3: Pharmaceuticals & Healthcare, Global, Deal Values (%), October 2013 19
Figure 4: Pharmaceuticals & Healthcare, Global, M&As, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 20
Figure 5: Pharmaceuticals & Healthcare, Global, M&As by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, May 2013 - October 2013 22
Figure 6: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 23
Figure 7: Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 25
Figure 8: Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 27
Figure 9: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, May 2013 - October 2013 29
Figure 10: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals (%), October 2013 31
Figure 11: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Deal Values (%), October 2013 32
Figure 12: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 33
Figure 13: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 35
Figure 14: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 37
Figure 15: Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), May 2013 - October 2013 39
Figure 16: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), May 2013 - October 2013 42
Figure 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, May 2013 - October 2013 44
Figure 18: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, May 2013 - October 2013 45
Figure 19:Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), May 2013 - October 2013 47
Figure 20:Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 49
Figure 21: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), May 2013 - October 2013 51
Figure 22: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 55
Figure 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), May 2013 - October 2013 57
Figure 24: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Number Of Deals, May 2013 - October 2013 59
Figure 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Deal Values (US$ m), May 2013 - October 2013 60
Figure 26:Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, by Upfront and Milestone Payments and Deal Values (US$ m), October 2013 61
Figure 27: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 63
Figure 28: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 67
Figure 29: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 70
Figure 30: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 73
Figure 31: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 76
Figure 32: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 81
Figure 33: Pharmaceuticals & Healthcare, Global, Hematological Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 84
Figure 34: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 87
Figure 35: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 91
Figure 36: Pharmaceuticals & Healthcare, Asia-Pacific, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 94
Figure 37: Pharmaceuticals & Healthcare, Rest of the World, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 97
Figure 38: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 100
Figure 39: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), May 2013 - October 2013 102

Upcoming Reports:

Greece: kiwi fruit market
By - Williams and Marshal Strategy
This report presents a comprehensive overview of the kiwi market in Greece and its state as of January 2014. It provides detailed analysis of the industry, its dynamics and structure. The purpose of the report is to describe the state of the kiwi market in Greece, to present actual and retrospective information about the volumes and dynamics of production, imports, exports and consumption, the characteristics of the market for the period 2008-2012 and to build a forecast for the market development until 2018. In the same way, the report presents an elaborate overview of the main market...
Poland: market of ceramic electrical insulators
By - Williams and Marshal Strategy
This report presents a comprehensive overview of the ceramic electrical insulators market in Poland and its state as of January 2014. It provides detailed analysis of the industry, its dynamics and structure. The purpose of the report is to describe the state of the ceramic electrical insulators market in Poland, to present actual and retrospective information about the volumes and dynamics of production, imports, exports and consumption, the characteristics of the market for the period 2008-2012 and to build a forecast for the market development until 2018. In the same way, the report...
Ozone Generation Technologies Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2012 - 2018
By - Transparency Market Research
The growing need to treat wastewater in order to make it usable for drinking and other purposes is propelling the growth of the ozone generation technologies market. Ozone technologies disinfect air/gas and wastewater (industrial and municipal), which can be further used for various purposes.  The global market is expected to witness steady growth over the next six years. Some of the major factors driving the demand for ozone generation technologies include water scarcity and the growing need to conserve natural water and treat wastewater. Favorable regulatory norms...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.us
Select License type:

Share this report

Related News

A Health Tech Incubator Started by GE Healthcare
Oct 30, 2014  
For the very first time, a health tech start up campus has been established by GE Healthcare at its headquarters at Helsinki, Finland. This area already has about twenty such healthcare start ups that are working on cloud services, wireless technologies, apps, and sensors that aim at improving healthcare. The main rationale behind such a step is providing opportunities for further...
Net Earnings of DuPont Increases 52% despite Agricultural Turmoil
Oct 29, 2014  
DuPont - The Wilmington, Del-based leading chemical company faced decline of three percent sales to $7.5 billion in the quarter ending of September 30. The company’s third-quarter earnings were increased by 52 percent to $433 million albeit the slow global growth and agricultural downside.   The company witnessed the biggest drags from chemical sales with eight percent...
Appeal for Sanitization in Construction Industry through Government Regulations: CIOB Ghana
Oct 29, 2014  
Rockson Dogbegah - The Chairman of the Chartered Institute of Building Ghana commented that the construction industry needs a thorough cleaning up and assurance of proper growth. Mr. Dogbegah also said that a few factors are extremely important for a proper development in the construction industry. These include keen adherence to standards, supreme sense of professionalism, and sheer pursuance...
Facebook Hints of Rise in Expenses in 2015, Shares Drop
Oct 29, 2014  
Facebook has announced on Tuesday that it is prepping for a dramatic rise in spending in the year 2015. This warning has come combined with a projected slowdown in the company’s revenues after revenues were analyzed at the end of the third quarter of the year. The plans of such hefty spending in the next financial year by the company are indicative of stress in the investor...
China to Invest in UKs Infrastructure Industry
Oct 28, 2014  
As per industry reports, it is expected that in the year 2015, the UK infrastructure will derive benefits from 105 billion pounds of Chinese money. This will involve a host of Chinese machinery suppliers, contractors, and materials producers. The UK government will be spending about half of 225 billion pounds on its own infrastructure. The investors from China will be investing...